Rafael Holdings, Inc. (NYSE:RFL) Short Interest Up 89.0% in July

Rafael Holdings, Inc. (NYSE:RFL) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 252,495 shares, a growth of 89.0% from the June 30th total of 133,570 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average trading volume of 317,195 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analyst Weigh In

RFL has been the topic of several research analyst reports. Weiss Ratings raised Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. Wall Street Zen raised Rafael to a “hold” rating in a research report on Saturday, July 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Rafael has an average rating of “Sell”.

Rafael Stock Down 6.0%

RFL opened at $1.98 on Thursday. The stock has a market cap of $102.70 million, a price-to-earnings ratio of -2.90 and a beta of 0.29. Rafael has a twelve month low of $1.12 and a twelve month high of $3.96. The company’s 50-day moving average price is $2.21 and its two-hundred day moving average price is $1.60.

Institutional Investors Weigh In On Rafael

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in Rafael by 72.9% during the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after purchasing an additional 190,179 shares during the period. Marshall Wace LLP bought a new stake in shares of Rafael in the second quarter valued at $50,000. Cable Car Capital LP bought a new stake in shares of Rafael in the second quarter valued at $173,000. Vanguard Group Inc. lifted its position in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after buying an additional 133,024 shares during the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of Rafael by 132.3% during the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after buying an additional 41,335 shares during the last quarter. Institutional investors own 11.30% of the company’s stock.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.